ASCO, page-31

Here we see Mr Myopia in action yet again.

Today Novogen/Kazia failed to attract two buyers or even a quota of two hundred dollars worth of sales. Yet he has to concern himself with the business of other companies. Go figure.

My wife has more cash in her purse as she settles down to watch some telly on a Monday night before bed than the stock market was prepared to risk today on the company he pumps ad nauseam.

In comparison, every Noxopharm capital raise has been well oversubscribed. With respect to the escrow of 46 Million NOX shares, large scale investors have been satisfied to leave their hard earned for a period of no less than two years - quite a feat in the drug development market space for a fledgling company.

No prizes for guessing the market reaction if the Novogen/Kazia board tomorrow offered a placement of 46M of its shares to be held under escrow for the next two years.

The news flow from the DARRT cohort scans is what is looming before NOX shareholders.

Now is not the time to be even thinking of selling.

Chances are those holding the above mentioned shares will be thinking likewise.